Quality of life and health status with zoledronic acid and generic alendronate - A secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass

Osteoporosis International

Volumn 23, Issue 7, 2012, Pages 2043-2051

  Hadji, P ^a   Ziller, V ^a   Gamerdinger, D ^b   Spieler, W ^c   Articus, K ^d   Baier, M ^d   Moericke, R ^e   Kann, P H ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Orthopedic Practice ^*  (Germany)

^c Research Center for Osteology and Rheumatology   (Germany)

^d NOVARTIS PHARMA GMBH   (Germany)

^e Endocrinologic Practice   (Germany)

Author keywords

Adherence; Generic alendronate status; Health; Quality of life; Zoledronic acid

Indexed keywords

ALENDRON HEXAL; ALENDRONIC ACID; GENERIC DRUG; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE MASS; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; DRUGS, GENERIC; FEMALE; HEALTH STATUS; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT PREFERENCE; PSYCHOMETRICS; QUALITY OF LIFE;

EID: 84863588052     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1834-4     Document Type: Article

References (36)

1. Bock O, Felsenberg D (2008) Bisphosphonates in the management of postmenopausal osteoporosis-optimizing efficacy in clinical practice. Clin Interv Aging 3:279-297.
2. Abrahamsen B, van Staa T, Ariely R et al (2009) Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int 20:1633-1650.
3. Cosman F (2009) Treatment of osteoporosis and prevention of new fractures: role of intravenously administered bisphosphonates. Endocr Pract 15:483-493.
4. Cramer JA, Gold DY, Silverman SL et al (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023-1031.
5. Ziller V, Wetzel K, Kyvernitakis I et al (2011) Adherence and persistence in patients with postmenopausal osteoporosis treated with raloxifene. Climacteric 14(2):228-235.
6. Ziller V, Zimmerman SP, Kalder M et al (2010) Adherence and persistence in patients with severe osteoporosis treated with teriparatide. Curr Med Res Opin 26:675-681.
7. Hadji P, Claus V, Ziller V et al (2011) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int. doi:10.1007/s00198-011-1535-z.
8. Landfeldt E, Ström O, Robbins S et al (2011) Adherence to treatment of primary osteoporosis and its association to fractures-the Swedish Adherence Register Analysis (SARA). Osteoporos Int. doi:10.1007/ s00198-011-1549-6.
9. Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013-1022.
10. Imaz I, Zegarra P, Gonzalez-Enriquez J et al (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21(11):1943-1951.
11. Höer A, Seidlitz C, Gothe H et al (2009) Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Pref Adherence 3:25-30.
12. Blouin J, Dragomir A, Moride Y et al (2009) Impact of noncompliance with alendronate and risedronate. Br J Clin Pharmacol 66:117-127.
13. CockerillW, Lunt M, Silman AJ et al (2004) Health-related quality of life and radiographic vertebral fracture. Osteoporos Int 15:113-119
14. . Cooper C, Jakob F, Chinn C et al (2008) Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). Osteoporos Int 19:493-501.
15. Boonen S, Vanderschueren D, Venken K et al (2008) Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. J Intern Med 264:315-332.
16. Cooper A, Drake J, Brankin E, Investigators PERSIST (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60:896-905.
17. Hadji P, Minne H, Pfeifer M et al (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 75:303-310.
18. Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822.
19. Lyles KW, Colón-Emeric CS, Magaziner JS (2007) Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 357:1799-1809.
20. Hadji P, Gamerdinger D, Spieler W et al (2011) Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass. Osteoporos Int. doi:10.1007/s00198-011-1583-4.
21. de Oliveira FN, Arthuso M, da Silva R et al (2009) Quality of life in women with postmenopausal osteoporosis: correlation between QUALEFFO 41 and SF-36. Maturitas 62:85-90.
22. Lips P, Jameson K, Bianchi ML, Working Group for Quality of Life of the International Osteoporosis Foundation et al (2010) Validation of the IOF quality of life questionnaire for patients with wrist fracture. Osteoporos Int 21(1):61-70.
23. Nevitt MC, Thompson DE, Black DM et al (2000) Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Arch Intern Med 160:77-85.
24. Cauley JA, Black D, Boonen S, et al (2010) Once-yearly zoledronic acid and days of disability, bed rest and back pain: randomised controlled HORIZON pivotal fracture trial. J Bone Miner Res epub ahead of prin.t.
25. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a randomized clinical trial. Multiple outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645.
26. Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541.
27. Kendler DL, McClung MR, Freemantle N et al (2011) Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 22(6):1725-1735.
28. Bartl R, Gotte S, Hadji P et al (2006) [Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment]. Dtsch Med Wochenschr 131:1257-1262.
29. Copher R, Buzinec P, Zarotsky V et al (2010) Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims. Curr Med Res Opin 26:777-785.
30. Ettinger MP, Gallagher R, MacCosbe PE (2006) Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract 12:522-528.
31. Cotté FE, Fardellone P, Mercier F et al (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145-155.
32. Wilkes MM, Navickis RJ, Chan WW et al (2010) Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials. Osteoporos Int 21:679-688.
33. Emkey R, Koltun W, Beusterien K et al (2005) Patient preference for once-monthly ibandronate in a randomized, open-label, crossover trial: the Bonviva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21:1895-1903.
34. Hadji P, Benhamou CL, Devas V et al (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 75 (3):303-310.
35. McClung M, Recker R, Miller P et al (2007) Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41:122-128.
36. Saag K, Lindsay R, Kriegman A et al (2007) A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 40:1238-1243